![Jordi Naval](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jordi Naval
Gründer bei Aelix Therapeutics SL
Ursprung des Netzwerks ersten Grades von Jordi Naval
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Aelix Therapeutics SL
![]() Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.
7
| Holding Company | Biotechnology | 7 |
Inprother ApS
![]() Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021.
2
| Holding Company | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jordi Naval
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
F. Hoffmann-La Roche Ltd.
![]() F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
IBEX TECHNOLOGIES | Medical Specialties | Director/Board Member | |
KALA BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Johnson & Johnson Innovation - JJDC, Inc.
![]() Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Private Equity Investor | |
Aelix, Inc.
![]() Aelix, Inc. Internet Software/ServicesTechnology Services Part of Billing Services Group Ltd., Aelix, Inc. provides intelligent communications solutions to enterprises, notably in the travel and hospitality, financial services, and electronic commerce sectors. The company is based in Los Angeles, CA. Aelix was acquired by Avery Communications, Inc. from ComF5 International, Inc. on December 04, 2001 for $4.10 million. | Internet Software/Services | Director/Board Member | |
University College Dublin | College/University | Undergraduate Degree | |
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Barcelona | College/University | Doctorate Degree | |
Universidad de Buenos Aires | College/University | Graduate Degree | |
Universität Konstanz | College/University | Doctorate Degree | |
LIFE HEALTHCARE GROUP HOLDINGS LIMITED | Hospital/Nursing Management | Director/Board Member | |
Altamar Private Equity SGIIC SA /Private Equity/
![]() Altamar Private Equity SGIIC SA /Private Equity/ Investment ManagersFinance Altamar Private Equity SGIIC SA (Altamar Private Equity) is a private equity arm of Altamar Capital Partners SL founded in 2004. The firm is headquartered in Spain with additional offices in New York and Santiago de Chile. | Investment Managers | Private Equity Investor | |
Ysios Capital Partners SGEIC SA
![]() Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
MERUS N.V. | Biotechnology | Director/Board Member | |
Caixa Capital Risc SGEIC SA
![]() Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Investment Managers | Private Equity Investor | |
Sanifit Therapeutics SA
![]() Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member | |
Mckinsey & Co., Inc. (Switzerland) | Corporate Officer/Principal | ||
Xeltis AG
![]() Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member | |
Seroba BioVentures Ltd.
![]() Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | Investment Managers | Private Equity Investor | |
Medlumics SL
![]() Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member | |
TopiVert Ltd.
![]() TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Galecto Biotech ApS
![]() Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
The Francis Crick Institute Ltd.
![]() The Francis Crick Institute Ltd. Medical/Nursing ServicesHealth Services The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Asceneuron SA
![]() Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Pulmocide Ltd.
![]() Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Minoryx Therapeutics SL
![]() Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member | |
Codagenix, Inc.
![]() Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | Medical/Nursing Services | Chief Executive Officer | |
Fundación Botín | Corporate Officer/Principal | ||
Horama SA
![]() Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Iproteos SL
![]() Iproteos SL Miscellaneous Commercial ServicesCommercial Services Iproteos SL engages in research and development for schizophrenia treatment. It specializes in the research and development of third-generation drugs for human diseases. The company was founded by Ernest Giralt and Teresa Tarragó and is headquartered in Barcelona, Spain. | Miscellaneous Commercial Services | Director/Board Member | |
SparingVision SAS
![]() SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Vivet Therapeutics SAS
![]() Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
AptaTargets SL
![]() AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Pharmaceuticals: Major | Director/Board Member | |
S-Biomedic NV
![]() S-Biomedic NV Household/Personal CareConsumer Non-Durables Part of maxingvest AG, S-Biomedic NV is a Belgian company that develops skin microbiome manipulation technology which allows to transplant beneficial bacteria on the skin. The company is based in Beerse, Belgium. The company was founded in 2014 by Bernhard Päetzold, Veronika Oudova, Marc Guëll. Veronika Oudova has been the CEO since 2014. S-Biomedic was acquired by Beiersdorf AG on December 16, 2022. | Household/Personal Care | Director/Board Member | |
GlyCardial Diagnostics SL
![]() GlyCardial Diagnostics SL Miscellaneous Commercial ServicesCommercial Services GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017. | Miscellaneous Commercial Services | Director/Board Member | |
SpliceBio SL
![]() SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Calypso Biotech BV
![]() Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Biotechnology | Director/Board Member | |
Sapreme Technologies BV
![]() Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | Biotechnology | Chairman | |
CytoKi Pharma ApS
![]() CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Centre For Genomic Regulation | Corporate Officer/Principal | ||
TRex Bio Ltd.
![]() TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Biotechnology | Director/Board Member | |
Exevir Bio BV
![]() Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Biotechnology | Chairman | |
AstriVax NV
![]() AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Biotechnology | Chairman | |
Inivata Ltd.
![]() Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Packaged Software | Director/Board Member |
Statistik
International
Spanien | 14 |
Vereinigtes Königreich | 8 |
Schweiz | 6 |
Vereinigte Staaten | 6 |
Belgien | 5 |
Sektoral
Health Technology | 29 |
Finance | 6 |
Commercial Services | 5 |
Consumer Services | 5 |
Health Services | 4 |
Operativ
Director/Board Member | 53 |
Chairman | 22 |
Corporate Officer/Principal | 13 |
Independent Dir/Board Member | 9 |
Chief Executive Officer | 8 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Thomas O. Hecht | 24 |
Sven Rohmann | 20 |
Jeanne Bolger | 20 |
Karen Wagner | 17 |
Pablo Cironi | 14 |
Philippe Monteyne | 10 |
J. Robert Coleman | 2 |
Christian Brander Silva | 1 |
Bonaventura Clotet | 1 |
- Börse
- Insiders
- Jordi Naval
- Unternehmensverbindungen